Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894494 | 1.00 | HTR7 (0.52) | HTR7RAB9AGRM4LMNASMN1; SMN2 | |
| SCHEMBL5661298 | 0.82 | HTR7 (0.58) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL1929353 | 0.82 | HTR7 (0.58) | HTR7RAB9AGRM4LMNASMN1; SMN2 | |
| SCHEMBL7690167 | 0.82 | KDM4E (0.46) | RAB9ALMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL10798879 | 0.80 | HTR7 (0.67) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL2344935 | 0.78 | HTR7 (0.64) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL701534 | 0.78 | HTR7 (0.64) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL74492 | 0.76 | HTR7 (0.57) | HTR7RAB9AGRM4LMNASMN1; SMN2 | |
| SCHEMBL6574822 | 0.76 | HTR7 (0.52) | HTR7RAB9AGRM4LMNASMN1; SMN2 | |
| SCHEMBL11107067 | 0.76 | HTR7 (0.52) | HTR7RAB9AGRM4LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10121974-B2 | Condensed-cyclic compound and organic light-emitting device comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-11-06 | — | — | US | disclosed |
| US-20160190449-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1961745-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | disclosed |
| EP-0851865-B1 | 12H-Dibenzo[d,g][1,3]dioxocine derivatives | NOVO NORDISK AS (DK) | 2002-07-17 | — | — | EP | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6017915-A | Heterocyclic compounds | NOVO NORDISK A/S (DK) | 2000-01-25 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| US-5916901-A | CLINICAL TREATMENT OF PAINFUL, HYPERALGESIC, INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE BY ELICITING NEUROGENIC PAIN | NOVO NORDISK A/S (DK) | 1999-06-29 | — | — | US | disclosed |
| US-5912262-A | Heterocyclic compounds | NOVO NORDISH A/S (DK) | 1999-06-15 | — | — | US | disclosed |
| EP-0851865-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-07-08 | — | — | EP | disclosed |
| US-5753678-A | Heterocyclic compounds | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997011071-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1997-03-27 | — | — | WO | disclosed |
| US-4134975-A | PYRIDO(1,2,-D)(1,4,6)BENZOXADIAZOCINES OR PYRIDO(1,2,-C)(1,3,5)BENZOXADIAZEPINES | E. R. SQUIBB & SONS, INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-3981886-A | Amino-benzimidazole derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3965101-A | CNS STIMULANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3957806-A | STIMULANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10121974-B2 | Condensed-cyclic compound and organic light-emitting device comprising the same | CCNT1, CRY1, CCNA1 | HTR7 2223/4885RAB9A 2904/4885GRM4 1854/4885 |
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRHR1, NR3C1, CNR1 | HTR7 248/4885RAB9A 1616/4885GRM4 64/4885 |
| US-20160190449-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE SAME | CCNT1, CRY1, CCNA1 | HTR7 2383/4885RAB9A 2803/4885GRM4 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.